ArticleFrontiers in oncology2025
Hsp70 regulates CD24 expression and promotes metastasis and invasion of lung cancer via the MAPK/ERK signaling pathway.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Study on the synergistic efficacy and mechanism of CD24 silencing combined with trastuzumab in HER2-positive breast cancer.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the effects and mechanisms of Hsp70-mediated regulation of CD24 expression on the invasion and metastasis of lung cancer. Methods: Protein-protein interactions between Hsp70 and CD24 were analyzed by co-immunoprecipitation and immunofluorescence. Lentiviral-mediated Hsp70 knockdown and CD24 overexpression were validated using RT-qPCR and Western blotting. Functional consequences were assessed through CCK-8 proliferation assays, colony formation, wound healing, Transwell migration/invasion, and angiogenesis assays. Results: Hsp70 and CD24 demonstrated interaction through co-precipitation. Knockdown of Hsp70 significantly attenuated CD24 expression (p<0.01), whereas CD24 overexpression did not alter Hsp70 levels. Phenotypically, Hsp70 suppression impaired cellular proliferation, migration, invasion and angiogenic capacity, while CD24 overexpression potentiated these oncogenic properties. Both manipulations modulated ERK1/2, MEK, Raf and Ras phosphorylation status. Conclusion: Hsp70 upregulates CD24 expression and activates downstream MAPK/ERK signaling, thereby enhancing the metastatic and invasive capacity of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.